AlphaNavi Pharma is developing a potent and selective voltage-gated sodium channel Nav1.7, Nav1.8 and Nav1.9 inhibitor, ANP-230, for neuropathic pain, including Nav-mutated rare pain diseases. It is has been reported that Nav1.7, Nav1.8 and Nav1.9 are mainly expressed in peripheral nervous system and gain-of function mutations of those Navs induce treatment-resistant rare pain diseases, including erythromelalgia and familial episodic limb pain. ANP-230 might be only one published clinical-stage compound which inhibits Nav1.9. In addition, due to high peripheral Nav selectivity and quite low penetration rate to blood-brain barrier, ANP-230 has less CV- and CNS-related side effects, while it still has potent analgesic efficacy. ANP-230 showed good tolerability in several Phase 1 studies in the US/UK and Japan and had proof-of mechanism signals in human pain challenge study. AlphaNavi Pharma is now conducting a Phase 1/2 study of ANP-230 for Nav1.9 mutated familial episodic limb pain in Japan. In parallel, we are seeking the opportunities of out-licensing to expand the clinical development of ANP-230 for neuropathic pain in the US, EU and China.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Enoki-Cho 33-94, Suita,osaka 564-0053,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.alphanavi.com/
- Keywords
- Shinjyuku.
- HQ
- Suita, Osaka
- Competitors
- Aculys Pharma, Neurotech Japan K.K., LIFESCAPES Inc., Asian Spine Brain Neurocare, Cancer Support France - Paris & Île-de-France, Spark Neuro Japan, SAWiN (South Asian Women in Neuroscience), France Cancer, 4th European Congress of Neurology and Neuropsychiatry, Asian American Psychological Association.
Alphanavi Pharma Inc. Questions
Alphanavi Pharma Inc.'s website is https://www.alphanavi.com/
Alphanavi Pharma Inc.'s LinkedIn profile is https://jp.linkedin.com/company/alphanavi-pharma-inc
Alphanavi Pharma Inc. has
5 employees.
View email and phone details for 5
employees at Alphanavi Pharma Inc..
Alphanavi Pharma Inc.'s industry is
Biotechnology Research
Alphanavi Pharma Inc.'s top competitors are
Aculys Pharma,
Neurotech Japan K.k.,
Lifescapes Inc.,
Asian Spine Brain Neurocare,
Cancer Support France - Paris & Île-De-France,
Spark Neuro Japan,
Sawin (South Asian Women In Neuroscience),
France Cancer,
4th European Congress Of Neurology And Neuropsychiatry,
Asian American Psychological Association.
Alphanavi Pharma Inc.'s categories are Biotechnology Research
Alphanavi Pharma Inc.'s founding year is 2019
